For patients who present with rhabdomyolysis, treatment is aimed at preventing kidney failure in the acute setting. Vigorous hydration with close monitoring of kidney function and electrolytes are paramount. In patients with an underlying metabolic myopathy, education about following a more moderate exercise program and avoiding intense exercise and fasting is necessary in preventing recurrent episodes. Measures that have been suggested to be helpful include sucrose loading before exercise in some glycogen storage disorders and a low-fat, high-carbohydrate diet in patients with lipid storage disorders.
Anderson and colleagues from St Thomas' Hospital , London, were the first to mention a case with possible clinical findings of LEMS in 1953,  but Lambert, Eaton, and Rooke at the Mayo Clinic were the first physicians to substantially describe the clinical and electrophysiological findings of the disease in 1956.   In 1972, the clustering of LEMS with other autoimmune diseases led to the hypothesis that it was caused by autoimmunity.  Studies in the 1980s confirmed the autoimmune nature,  and research in the 1990s demonstrated the link with antibodies against P/Q-type voltage-gated calcium channels.  
Physical therapy is directed at preventing atrophy and contractures, and is particularly necessary in patients with calcinosis and muscle involvement. Technique should focus initially on passive stretching and splinting, with inclusion of more aggressive strength-building therapy once inflammation is controlled. The use of a broad-spectrum sunscreen is recommended in all patients with dermatomyositis and has the greatest benefit in patients who are photosensitive. Sun-avoidance techniques should be used, including the use of protective clothing. For control of severe pruritus, antihistamines (such as hydroxyzine [Atarax] or doxepin [Sinequan]) are recommended. For further control of the erythematous and pruritic skin changes, a class I (super-high potency) or class II (high potency) topical corticosteroid is recommended. 3 , 10